BBIO · NASDAQ
BBIO · NASDAQ
74.93 USD
+4.20 (+5.93%)
After hours 74.20 USD -0.73 (-0.97%)
No new catalyst: BBIO is now up about 5.8%, deeper than the roughly 2.9% move earlier, as investors continued to react to its third-quarter beat. Revenue reached $353.2 million, led by Attruby sales and a Bayer milestone, while the adjusted loss of $0.42 per share beat the consensus loss estimate. BridgeBio's quarterly results Healthcare peers also traded higher, though BBIO rose as the broader market sold off.
No new catalyst: BBIO is now up about 5.8%, deeper than the roughly 2.9% move earlier, as investors continued to react to its third-quarter beat. Revenue reached $353.2 million, led by Attruby sales and a Bayer milestone, while the adjusted loss of $0.42 per share beat the consensus loss estimate. BridgeBio's quarterly results Healthcare peers also traded higher, though BBIO rose as the broader market sold off.